Annmarie Gaskin
Neurology · Chester, PANPI 1275694085
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 139 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,661 and has fallen 96.7% since, to $55 in 2025.
Across 139 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$392
- Sunovion Pharmaceuticals Inc.$344
- Novartis$249
- Teva Pharmaceuticals USA, Inc.$130
- Harmony Biosciences LLC$107
- Jazz Pharmaceuticals Inc.$104
- plus $824 from 19 others
What the payments were for
- Food & beverage$2,10498%
- Education$452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 36 | $392 |
| Sunovion Pharmaceuticals Inc. | 22 | $344 |
| Novartis | 16 | $249 |
| Teva Pharmaceuticals USA, Inc. | 12 | $130 |
| Harmony Biosciences LLC | 4 | $107 |
| Jazz Pharmaceuticals Inc. | 6 | $104 |
| UCB, Inc. | 6 | $95 |
| Avanir Pharmaceuticals, Inc. | 5 | $89 |
| AbbVie(2 entities) | 5 | $86 |
| Eisai Inc. | 4 | $85 |
| Greenwich Biosciences, Inc. | 3 | $65 |
| Lilly USA, LLC | 4 | $62 |
| International Rehabilitative Sciences, Inc | 1 | $55 |
| Amgen | 2 | $52 |
| Sanofi | 2 | $40 |
| Biohaven Pharmaceuticals, Inc. | 1 | $34 |
| Acadia Pharmaceuticals Inc | 2 | $31 |
| Merz North America, Inc. | 1 | $20 |
| Boston Scientific | 1 | $19 |
| CSL Behring | 1 | $18 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
| Resmed Corp | 1 | $16 |
| Strongbridge US Inc. | 1 | $14 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
| GSK | 1 | $12 |
How this compares
$2,149 in reported general payments places this provider in the 60th percentile of 941 neurology providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FingolimodFingolimod Hcl | 12 | $3,180 |
| Carbamazepine ErCarbamazepine | 11 | $1,324 |
Paid to pharmacies, not to this prescriber.
Other neurology in Chester
- Daniel KremensPhiladelphia$1.8M
- Thomas LeistPhiladelphia$1.4M
- Jill Giordano FarmerPhiladelphia$1.2M
- Ravi DukkipatiYork$936K
- Brad KleinAbington$927K
- Stephanie Nahas-GeigerPhiladelphia$786K
- John KhouryAbington$686K
- Amit Bar-OrPhiladelphia$596K
- Behrang SaminejadAllentown$594K
- Anoopum GuptaPittsburgh$592K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.